Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SERPASIL-APRESOLINE vs ALDORIL 15
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases c GMP via NO).
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Hypertension
Hypertension
1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
Reserpine: ~50-100 hours (biphasic; terminal phase 4.5-11 days due to enterohepatic circulation and tissue binding). Hydralazine: 2-8 hours (rapid acetylators 30-50 min, slow acetylators 2-8 hours); longer in renal impairment.
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Reserpine: hydrolyzed in gut, metabolites excreted in urine. Hydralazine: N-acetylation via NAT2.
Methyldopa is metabolized in the liver via conjugation and O-methylation; active metabolites include methyldopamine and methylnorepinephrine. Hydrochlorothiazide is not significantly metabolized and is excreted unchanged in urine.
Reserpine: <1% unchanged in urine; extensive hepatic metabolism followed by renal and fecal excretion. Hydralazine: 80-90% renal; 10% fecal; 1-2% unchanged in urine; polymorphic acetylation (rapid/slow acetylators) affects clearance.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Reserpine: ~96% (bound to albumin and α1-acid glycoprotein). Hydralazine: 85-90% (primarily albumin; also binds to α1-acid glycoprotein and lipoproteins).
~90%, primarily to albumin
Reserpine: ~8-10 L/kg (extensive tissue binding, especially adipose and brain). Hydralazine: 1.5-8 L/kg (increases with hypertension; reflects high tissue distribution).
2–4 L/kg; clinical meaning: extensive tissue distribution, concentrating in vascular smooth muscle
Reserpine: 5-30% oral (extensive first-pass metabolism; variable). Hydralazine: 30-50% oral (slow acetylators have higher bioavailability due to reduced first-pass acetylation; rapid acetylators 10-30%).
Oral: 50–60% (extensive first-pass metabolism)
GFR <30 m L/min: Use with caution; reduce hydralazine component by 50%. GFR 30-50 m L/min: No adjustment needed for hydralazine; reserpine use contraindicated if severe renal impairment.
GFR 30-50 m L/min: maximum 1 tablet twice daily. GFR <30 m L/min: avoid use.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce hydralazine dose by 50%. Child-Pugh C: Contraindicated due to risk of encephalopathy from reserpine and hepatotoxicity.
Child-Pugh A: caution, reduce dose. Child-Pugh B: avoid. Child-Pugh C: contraindicated.
Weight-based: 0.01 mg/kg reserpine and 2.5 mg/kg hydralazine per day orally, divided into 1-2 doses. Maximum: reserpine 0.25 mg/day, hydralazine 50 mg/day.
Not recommended for pediatric use; safety in children under 12 years not established.
Start at half the adult dose (1 tablet every other day) due to increased sensitivity to hypotension and CNS depression. Monitor for orthostatic hypotension and electrolyte imbalances.
Start with 1 tablet once daily; monitor for hypotension and electrolyte imbalance. Reduce initial dose by 50%.
None
None
Reserpine may cause depression, peptic ulcer, or arrhythmias.,Hydralazine may cause drug-induced lupus, peripheral neuritis, or orthostatic hypotension.,Monitor for hypotension and renal impairment.
Sedation, usually transient; may impair ability to drive or operate heavy machinery.,Positive Coombs test with hemolytic anemia (rare); monitor hematocrit and Coombs test.,Hepatotoxicity (hepatic necrosis) with fever, jaundice; discontinue if liver abnormalities occur.,Fluid and electrolyte imbalance (hypokalemia, hyponatremia, hypercalcemia) due to thiazide.,May precipitate gout in hyperuricemic patients.,May exacerbate systemic lupus erythematosus.
Hypersensitivity to reserpine or hydralazine,Active peptic ulcer,Ulcerative colitis,Depression, especially with suicidal tendencies,Coronary artery disease (hydralazine may cause tachycardia)
Active hepatic disease (e.g., acute hepatitis, cirrhosis),Prior methyldopa therapy associated with liver disorders,Hypersensitivity to methyldopa or hydrochlorothiazide,Anuria,Sulfonamide allergy (cross-sensitivity with thiazides)
Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products, soy sauce, beer, wine) due to MAO inhibition from reserpine component; however, risk is lower than classical MAOIs. Avoid alcohol. Limit foods high in sodium to prevent fluid retention.
Avoid high-sodium foods as they can reduce antihypertensive efficacy. Thiazides may cause hypokalemia; increase dietary potassium (bananas, orange juice) unless contraindicated. Alcohol may enhance orthostatic hypotension.
First trimester: Limited data; beta-blockers (reserpine component) associated with fetal bradycardia and growth restriction. Second/third trimester: Hydralazine and reserpine may cause neonatal hypotension, bradycardia, and hypothermia. Reserpine may increase risk of neonatal respiratory depression and nasal congestion.
First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: Fetal and neonatal adverse effects including oligohydramnios, fetal renal dysfunction, skull ossification delay, and hypotension in the neonate. Avoid use after 20 weeks gestation unless no alternative.
Reserpine and hydralazine are excreted in breast milk. M/P ratio not well established. Reserpine may cause adverse effects in infants (diarrhea, nasal congestion). Hydralazine is considered compatible with caution. Avoid or use alternative antihypertensives with more safety data.
Methyldopa and hydrochlorothiazide are excreted into human milk. M/P ratio for methyldopa is approximately 0.5-1.0; for hydrochlorothiazide, M/P ratio ~2.0. Methyldopa is considered compatible with breastfeeding. Hydrochlorothiazide may suppress lactation and cause neonatal electrolyte disturbances. Use with caution; monitor infant for signs of diuresis or electrolyte imbalance.
Pregnancy may alter pharmacokinetics of hydralazine (increased clearance) and reserpine (limited data). Dose adjustments may be needed based on blood pressure response. Avoid use in pregnancy if possible; no standard recommended dose adjustments.
Pharmacokinetic changes in pregnancy may include increased volume of distribution and enhanced renal clearance. No specific dose adjustment routine is recommended; dosing should be guided by clinical response. Methyldopa starting dose 250 mg twice daily, titrated to effect. Hydrochlorothiazide dose not typically adjusted, but caution due to potential volume depletion.
Serpasil-Apresoline is a fixed-dose combination of reserpine and hydralazine, both antihypertensives with complementary mechanisms. Reserpine depletes catecholamines and serotonin, while hydralazine is a direct vasodilator. This combination is rarely used today due to poor tolerability (significant CNS depression, depression risk) and availability of better-tolerated agents. Monitor for orthostatic hypotension, bradycardia, and signs of depression. Avoid in patients with history of depression, peptic ulcer disease, or MAOI use. Abrupt withdrawal can cause hypertensive crisis.
Aldoril 15 (methyldopa 250mg + hydrochlorothiazide 15mg) is rarely used due to superior alternatives. Monitor for hepatotoxicity, hemolytic anemia, and lupus-like syndrome. Titrate slowly to avoid sedation. Contraindicated in active liver disease, pheochromocytoma, and anuria.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause dizziness or lightheadedness; rise slowly from sitting or lying positions.,Avoid alcohol and other central nervous system depressants.,Report any persistent fatigue, mood changes, or signs of depression.,May cause nasal congestion; do not use decongestants without consulting doctor.,Avoid prolonged sun exposure; may increase skin photosensitivity.,Contact doctor if you experience swelling of ankles/feet, weight gain, or shortness of breath.,Store at room temperature away from moisture and light.
May cause drowsiness; avoid driving until tolerance develops.,Report unexplained fever, jaundice, or dark urine immediately.,Take at bedtime to minimize sedation.,Avoid sudden discontinuation; follow prescribed tapering schedule.,Use sun protection; thiazides increase photosensitivity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SERPASIL-APRESOLINE vs ALDORIL 15, answered by our medical review team.
SERPASIL-APRESOLINE is a Antihypertensive Combination that works by Combination of reserpine (depletes catecholamines from sympathetic nerve endings) and hydralazine (direct vasodilator, increases c GMP via NO).. ALDORIL 15 is a Antihypertensive Combination that works by Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SERPASIL-APRESOLINE and ALDORIL 15 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SERPASIL-APRESOLINE is: 1 tablet (containing reserpine 0.1 mg and hydralazine 25 mg) orally once daily; may increase to twice daily if needed. Maximum dose: 2 tablets per day.. The standard adult dose of ALDORIL 15 is: 1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SERPASIL-APRESOLINE and ALDORIL 15 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SERPASIL-APRESOLINE is classified as Category C. First trimester: Limited data; beta-blockers (reserpine component) associated with fetal bradycardia and growth restriction. Second/third trimester: Hydralazine and reserpine may c. ALDORIL 15 is classified as Category C. First trimester: No increased risk of major malformations based on limited human data; animal studies show no teratogenicity at clinically relevant doses. Second/third trimesters: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.